Selling pressure pushes Tilray stock lower in today's trading

Traders Union
All News
Financial News
Tilray slides 2.01% today to $6.60

Highlights

Tilray posted record quarterly revenue with muted 3% year-over-year growth, while significant net losses and negative adjusted free cash flow persist.
Recent beverage expansions, new Australian medical cannabis products, and the BrewDog UK asset deal failed to prevent a share price decline amid regulatory uncertainty.
Shares remain under strong bearish momentum, trading below key averages, with the next five-session range likely between $6.30 and $6.50.

Price weakness intensifies despite record revenue and business expansions

Tilray reported record revenue for the recent period, though year-over-year growth was limited to 3%, with significant net losses and negative adjusted free cash flow also recorded. The company expanded its beverage business through Breckenridge Distillery launches at Colorado Cheba Hut locations and initiated new partnerships, including an agreement to acquire parts of UK brewer BrewDog, an announcement followed by a share price decline. Tilray also announced its largest medical cannabis portfolio expansion to date in Australia, while ongoing regulatory uncertainties and financial challenges remained central factors, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees Tilray under persistent selling pressure and technical weakness. He notes that shares are well below key moving averages and major indicators remain deeply bearish. Kharitonov also highlights the disappointing margin despite record revenue, pointing to only modest growth and recurring net losses. He considers the negative market response to acquisitions and ongoing regulatory risks as warning signs. "Given sustained negative momentum and unresolved fundamental challenges, I see further downside risk for Tilray until a robust catalyst emerges."

Viktoras Karapetjanc, expert at Traders Union, acknowledges Tilray’s modest year-over-year growth and continued operational expansion. He believes new partnerships, including the BrewDog deal and expansion in Australia, position Tilray for future diversification and international scale. Karapetjanc sees the beverage business and medical cannabis portfolio as strategic levers for long-term gains. He expects that stronger fundamentals may spark investor interest once market sentiment stabilizes. "Despite near-term volatility, I see multiple promising setups on the horizon as the bullish structure remains intact for forward-looking investors."

Parshwa Turakhiya, analyst, observes that Tilray is trading deep in oversold territory with short-term momentum favoring bears. He finds that immediate resistance near $7.52 looms large, capping potential relief rallies. Turakhiya notes moderate intraday volatility and a critical support at $6.30 defining the current risk-reward play. "With sellers in control but oversold signals flashing, I expect tactical bounces may emerge, but caution is key for now."

Bearish momentum dominates as technicals signal oversold but weak support

Tilray shares are currently trading at $6.60, well below the SMA-20 ($7.38), SMA-50 ($7.96), and SMA-200 ($9.45), confirming persistent downward momentum across all timeframes. The Ichimoku Kijun line at $7.52 acts as the nearest dynamic resistance, while no significant support is indicated above the current price. Momentum is decisively negative, with both MACD and ADX (D1) suggesting weak and bearish conditions. RSI at 33.94, Stoch RSI at extreme oversold, and CCI below –100 all point to an oversold environment, but sellers still dominate according to BBP. The AO also supports a persistent bearish trend. Today, the price opened slightly lower than the previous close, indicating a small gap down. As of the observation time, shares are trading near the middle of today’s $6.47 – $6.70 range. Intraday volatility has been moderate, with continued downside pressure apparent after the open. Daily performance and momentum signals are aligned, reinforcing a bearish short-term tone.

Earlier, analysts noted that Tilray faced persistent seller pressure and bearish technical momentum despite efforts to diversify through beverage expansion and new partnerships. The current setup not only reinforces this negative outlook with further declines and oversold signals, but also highlights the importance of monitoring the $6.30 support level, as a breakdown could accelerate additional downside risk.

Source of Data: TLRY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.